Showing results (1-10 of 490) with videos related to

Sort By:
Pageof 49
The Journal of Clinical Endocrinology and Metabolism|February 18, 1999
Serum cytokines in thyrotoxicosisA Siddiqi, J P Monson, D F Wood, et al.
Clinical Endocrinology|October 23, 2002
Pancreatic lesions in von Hippel-Lindau diseaseB Mukhopadhyay, A Sahdev, J P Monson, et al.
Hormone Research|October 13, 2004
Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LARP J Jenkins, M Emery, S J Howling, et al.
Clinical Endocrinology|April 18, 2003
The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarismA M Isidori, G A Kaltsas, L Perry, et al.
European Journal of Endocrinology|October 3, 2001
Successful treatment of resistant acromegaly with a growth hormone receptor antagonistW M Drake, C Parkinson, S A Akker, et al.
Clinical Endocrinology|January 13, 2001
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titrationP J Jenkins, S Akker, S L Chew, et al.
European Journal of Endocrinology|March 15, 2005
Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomantW M Drake, R A Loureiro, C Parkinson, et al.
The Journal of Clinical Endocrinology and Metabolism|December 16, 1998
The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumorsG A Kaltsas, J J Mukherjee, P N Plowman, et al.
The Journal of Clinical Endocrinology and Metabolism|July 10, 2001
Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegalyP J Trainer, W M Drake, L A Perry, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2000
Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatmentP Putignano, G A Kaltsas, M Korbonits, et al.
Pageof 49